Author:
Douma L.H.,Baas P.,de Gooijer C.J.
Reference11 articles.
1. Real-world efficacy and safety of combination nivolumab plus ipilimumab for untreated, unresectable, pleural mesothelioma: The meso-immune (GFPC04-2021) Trial;Bylicki;Lung Cancer,2024
2. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021
3. Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study;Chow;Asia Pac. J. Clin. Oncol.,2022
4. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting;Waterhouse;Future Oncol,2021
5. P2.18-04 Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso);Aguirre;J. Thorac. Oncol.,2023